highly significantP > 0.05
After 12 months of follow-up, WBC, RBC, hemoglobin, PLTs, HCT, lymphocytes, and basophils showed highly significant results ( P > 0.05) against the drug imatinib mesylate ( Table 5 ).
After 12 months of follow-up, WBC, RBC, hemoglobin, PLTs, HCT, lymphocytes, and basophils showed highly significant results ( P > 0.05) against the drug imatinib mesylate ( Table 5 ).